CAMZYOS® Echocardiogram Scheduling Tool

A patient’s most recent dispense or echo date, a treatment interruption, initiation of a concomitant weak to moderate CYP2C19 inhibitor or moderate to strong CYP3A4 inhibitor, or a change in their CAMZYOS dose will all influence the echocardiogram cadence.1 This tool can help you estimate a date for the patient's next echocardiogram(s) during the initiation phase, but it does not schedule the appointment(s). For patients who delay treatment initiation up to 90 days from Patient Enrollment Form submission: Assess the patient’s treatment start date. Document and submit the new start date using the REMS Portal.

As required by the CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) program, patients must be enrolled in the program
before they can be prescribed. Patient Status Forms must also be submitted after every echo.1 For more information, visit CAMZYOSREMS.com.

NOTE: The estimated date range(s) within the tool may not apply if there are changes in dose of CAMZYOS, a break in treatment, and/or after initiation of certain medicines (weak to moderate CYP2C19 or moderate to strong CYP3A4 inhibitors) that are known to affect CAMZYOS.1 For more details on how these events affect a patient’s echocardiogram schedule, please see section 2 in the Full Prescribing Information and Dosing Schematic.1

The CAMZYOS Echocardiogram Scheduling Tool is not an official component of the CAMZYOS REMS Program, but rather an online tool to assist in estimating echocardiogram date range(s) during the initiation phase. All REMS activities must be completed in the REMS Portal.

CAMZYOS REMS resources can be found here.

Enter the patient's treatment start date:
MM/DD/YYYY
Please see the Dosing Guide
Which date range(s) would you like to estimate for the patient's initiation phase echocardiograms(s)?
Select all that apply.



Show the estimated dates
CAMZYOS echo schedule1
CAMZYOS® Echocardiogram Scheduling Tool
Suggested date(s) range to schedule a clinical visit and a follow-up
echocardiogram based on date entered.
During the initiation phase, echocardiograms should be performed at weeks 4, 8, and 12. Please see Section 2 of the USPI for dosing and administration guidance for echos needed after week 12.1 Echocardiograms may also be needed after a change in the dose of CAMZYOS, a break in treatment, and/or after starting certain medicines that are known to affect CAMZYOS.1
NOTE: The estimated date range(s) within the tool may not apply if there are changes in dose of CAMZYOS, a break in treatment, and/or after initiation of certain medicines (weak to moderate CYP2C19 or moderate to strong CYP3A4 inhibitors) that are known to affect CAMZYOS.1 For more details on how these events affect a patient’s echocardiogram schedule, please see section 2 in the Full Prescribing Information and Dosing Schematic.1
Missed or delayed appointments may result in treatment interruption. Initiation or up-titration of CAMZYOS in patients with LVEF <55% is not recommended. If LVEF is <50% while taking CAMZYOS, interrupt treatment.1
The CAMZYOS Echocardiogram Scheduling Tool is not an official component of the CAMZYOS REMS Program, but rather an online tool to assist in estimating echocardiogram date range(s) in the Initiation Phase. For more information on echo scheduling past Week 12, please see the Full Prescribing information or the REMS Portal. All REMS activities must be completed in the REMS Portal.
Recalculate with different date
Print estimated dates

LVEF=left ventricular ejection fraction; REMS=Risk Evaluation and Mitigation Strategy.

Prior to initiation1 

  • Assess LVEF by echo. Do not initiate treatment if LVEF <55% 
  • Confirm absence of pregnancy and advise females of reproductive potential to use effective contraception until 4 months after the last dose. Use a contraceptive not affected by CYP450 enzyme induction or add nonhormonal contraception 
  • Consider contraindications and drug interactions prior to and throughout treatment 
  • To prescribe CAMZYOS, you must be certified in the CAMZYOS REMS program. Learn more at CAMZYOSREMS.com 

Following initiation1

  • Patients may develop heart failure while taking CAMZYOS. Regular LVEF and Valsalva LVOT gradient assessment is required for careful dose titration to achieve an appropriate target Valsalva LVOT gradient while maintaining LVEF ≥50%

3500-US-2500118 04/25

Reference:

  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  2. CAMZYOS REMS. Patient Status Form. Accessed April 18, 2025. https://www.camzyosrems.com/assets/commercial/us/camzyosrems/en/pdf/Camzyos-Patient-Status-Form.pdf


© 2025 MyoKardia, Inc., a Bristol Myers Squibb company. 
CAMZYOS® and the CAMZYOS and MyCAMZYOS Logos are trademarks of MyoKardia, Inc.

3500-US-2400621   04/25

This site is intended for U.S. Healthcare Professionals only.